MARKET

RIGL

RIGL

Rigel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.750
+0.005
+0.13%
Opening 14:05 01/22 EST
OPEN
3.700
PREV CLOSE
3.745
HIGH
3.800
LOW
3.700
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
5.24
52 WEEK LOW
1.230
MARKET CAP
633.48M
P/E (TTM)
-22.7549
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Glomerulonephritis Treatment Market 2021 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, Covid-19 Impact Analysis on Key Country Forecast to 2025
Jan 22, 2021 (The Expresswire) -- Global "Glomerulonephritis Treatment Market" (2021) report revolves around the significant makers of the Glomerulonephritis...
The Express Wire · 10h ago
8-K: RIGEL PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- 0001034842 false 0001034842 2021-01-11 2021-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/12 04:52
Rigel (RIGL) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rigel (RIGL) today and set a price target of $8.00. The company's shares closed last
SmarterAnalyst · 01/11 16:32
*DJ Rigel Pharma: Expect to Report Cash, Cash Equivalents and Short-Term Investments as of Dec 31 of About $57.3M
Dow Jones · 01/11 12:38
*DJ Rigel Pharma Sees 4Q Total Revenue of About $18.4M
Dow Jones · 01/11 12:37
Rigel Expects To Report Q4 Sales Of $18.4 M
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today provided a business update, including preliminary total revenue, TAVALISSE® (fostamatinib
Benzinga · 01/11 12:34
Rigel Pharmaceuticals Provides Business Update
, Jan. 11, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, including preliminary total revenue, TAVALISSE (fostamatinib disodium hexahydrate) bottles sold for the quarter, Fast Track designation granted for...
PR Newswire - PRF · 01/11 12:30
Rigel Pharmaceuticals Provides Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, including preliminary total revenue, TAVALISSE® (fostamatinib disodium hexahydrate) bottles sold for the quarter, Fast Track designation granted for warm autoimmune hemolytic anem...
PR Newswire · 01/11 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RIGL. Analyze the recent business situations of Rigel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RIGL stock price target is 7.33 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 199
Institutional Holdings: 153.51M
% Owned: 90.87%
Shares Outstanding: 168.93M
TypeInstitutionsShares
Increased
36
13.77M
New
41
-3.34M
Decreased
50
15.61M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+0.81%
Key Executives
President/Chief Executive Officer/Director
Raul Rodriguez
Chief Financial Officer/Executive Vice President
Dean Schorno
Executive Vice President/General Counsel/Secretary
Dolly Vance
Executive Vice President
Wolfgang Dummer
Executive Vice President
David Santos
Senior Vice President
Esteban Masuda
Independent Director
Bradford Goodwin
Independent Director
Keith Katkin
Independent Director
Brian Kotzin
Independent Director
Gregg Lapointe
Independent Director
Gary Lyons
Independent Director
Walter Moos
Independent Director
Jane Wasman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RIGL
Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
More

Webull offers kinds of Rigel Pharmaceuticals, Inc. stock information, including NASDAQ:RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.